![conference banner](/images/conference-banner.jpeg)
Abstract
Angiogenesis, the formation of blood vessels from preexisting ones, plays a crucial role in tumor progression. Activation of an “angiogenic switch” allows tumor cells to invade and metastasize. The growing interest in the use of antiangiogenic agents in the treatment and prevention of cancer lies in the theoretical advantages of this molecularly targeted modality of chemotherapy. Delivery of antiangiogenic agents are not complicated by having to penetrate large bulky masses but, instead, have easy access to tumoral endothelial cells. Antiangiogenic drugs may not cause cytopenias and thus will avoid many of the unwarranted toxicities of standard chemotherapeutic agents. Because they act directly on nascent endothelial cells, antiangiogenic agents may avoid tumor resistance mechanisms. If antiangiogenic agents are successful, they might be applicable to many tumor types and not be dependent on cell type or growth fraction of cells within a tumor. However, several important obstacles remain with regards to using antiangiogenic drugs in clinical trials with which we must contend in order to determine accurately the efficacy of these agents. In this article, we review the different classes of antiangiogenic agents available, ongoing clinical trials, as well as potential pitfalls and future directions in this exciting field.
Keywords: angiogenesis, antiangiogenesis, antiangiogenic, antiangiogenic therapy, antiangiogenic agents, chemoprevention
Current Pharmaceutical Design
Title: Antiangiogenic Therapy
Volume: 10 Issue: 1
Author(s): Daniel Albo, Thomas N. Wang and George P. Tuszynski
Affiliation:
Keywords: angiogenesis, antiangiogenesis, antiangiogenic, antiangiogenic therapy, antiangiogenic agents, chemoprevention
Abstract: Angiogenesis, the formation of blood vessels from preexisting ones, plays a crucial role in tumor progression. Activation of an “angiogenic switch” allows tumor cells to invade and metastasize. The growing interest in the use of antiangiogenic agents in the treatment and prevention of cancer lies in the theoretical advantages of this molecularly targeted modality of chemotherapy. Delivery of antiangiogenic agents are not complicated by having to penetrate large bulky masses but, instead, have easy access to tumoral endothelial cells. Antiangiogenic drugs may not cause cytopenias and thus will avoid many of the unwarranted toxicities of standard chemotherapeutic agents. Because they act directly on nascent endothelial cells, antiangiogenic agents may avoid tumor resistance mechanisms. If antiangiogenic agents are successful, they might be applicable to many tumor types and not be dependent on cell type or growth fraction of cells within a tumor. However, several important obstacles remain with regards to using antiangiogenic drugs in clinical trials with which we must contend in order to determine accurately the efficacy of these agents. In this article, we review the different classes of antiangiogenic agents available, ongoing clinical trials, as well as potential pitfalls and future directions in this exciting field.
Export Options
About this article
Cite this article as:
Albo Daniel, Wang N. Thomas and Tuszynski P. George, Antiangiogenic Therapy, Current Pharmaceutical Design 2004; 10 (1) . https://dx.doi.org/10.2174/1381612043453522
DOI https://dx.doi.org/10.2174/1381612043453522 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
Blood-based biomarkers in large-scale screening for neurodegenerative diseases
Disease biomarkers are necessary tools that can be employ in several clinical context of use (COU), ranging from the (early) diagnosis, prognosis, prediction, to monitor of disease state and/or drug efficacy. Regarding neurodegenerative diseases, in particular Alzheimer’s disease (AD), a battery of well-validated biomarkers are available, such as cerebrospinal fluid ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Diabetes mellitus: advances in diagnosis and treatment driving by precision medicine
Diabetes mellitus (DM) is a chronic degenerative metabolic disease with ever increasing prevalence worldwide which is now an epidemic disease affecting 500 million people worldwide. Insufficient insulin secretion from pancreatic β cells unable to maintain blood glucose homeostasis is the main feature of this disease. Multifactorial and complex nature of ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
![Wayfinder Image](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Particle Sorting in Microfluidic Systems
Micro and Nanosystems The Interest of Folic Acid in Targeted Photodynamic Therapy
Current Medicinal Chemistry The IFN-λ Family (IL-28/29)
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Protein-Protein Interactions: Recent Progress in the Development of Selective PDZ Inhibitors
Current Chemical Biology DNA Intercalators in Cancer Therapy: Organic and Inorganic Drugs and Their Spectroscopic Tools of Analysis
Mini-Reviews in Medicinal Chemistry Mechanisms of the Penetration of Blood-Borne Substances into the Brain
Current Neuropharmacology Synthesis and in vitro Evaluation of the Anticancer Potential of New Aminoalkanol Derivatives of Xanthone
Anti-Cancer Agents in Medicinal Chemistry Withdrawal Notice: Drug Repurposing for Prospective Anti-Cancer Agents Along with the Clinical Status of the Repurposed Drug
Anti-Cancer Agents in Medicinal Chemistry Synthesis of Aryl-Substituted Naphthalenoids as Potent Topoisomerase Inhibitors
Medicinal Chemistry Genomics and Cancer Drug Resistance
Current Pharmaceutical Biotechnology Current Targets for Anticancer Drug Discovery
Current Drug Targets Synthesis and Biological Evaluation of New Piperazine Substituted 3, 5-Diarylisoxazolines
Current Organic Synthesis Potential Therapeutic Targets of Curcumin, Most Abundant Active Compound of Turmeric Spice: Role in the Management of Various Types of Cancer
Recent Patents on Anti-Cancer Drug Discovery Observations on the Use of the Avian Chorioallantoic Membrane (CAM) Model in Investigations into Angiogenesis
Current Drug Targets - Cardiovascular & Hematological Disorders The Eker Rat: Establishing a Genetic Paradigm Linking Renal Cell Carcinoma and Uterine Leiomyoma
Current Molecular Medicine Molecular Signature of HPV-Induced Carcinogenesis: pRb, p53 and Gene Expression Profiling
Current Genomics Tobacco, Inflammation, and Respiratory Tract Cancer
Current Pharmaceutical Design Induction of Autophagic Cell Death in Apoptosis-resistant Pancreatic Cancer Cells using Benzo[α]phenoxazines Derivatives, 10-methyl-benzo[α]phenoxazine-5-one and benzo[α]phenoxazine-5-one
Anti-Cancer Agents in Medicinal Chemistry Recent Patents and Patent Applications Relating to mTOR Pathway
Recent Patents on DNA & Gene Sequences SV40 and HIV Sequences in the Cerebrospinal Fluid of a Patient with AIDS Dementia Complex
Current HIV Research